S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
NASDAQ:LUMO

Lumos Pharma (LUMO) Stock Price, News & Analysis

$2.82
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$2.82
$2.94
50-Day Range
$2.66
$3.15
52-Week Range
$2.51
$4.55
Volume
8,854 shs
Average Volume
26,772 shs
Market Capitalization
$22.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Lumos Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
538.3% Upside
$18.00 Price Target
Short Interest
Bearish
6.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$1,327 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.80) to ($2.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.34 out of 5 stars

Medical Sector

614th out of 938 stocks

Pharmaceutical Preparations Industry

290th out of 435 stocks

LUMO stock logo

About Lumos Pharma Stock (NASDAQ:LUMO)

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

LUMO Stock Price History

LUMO Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Q4 2023 Lumos Pharma Inc Earnings Call
Lumos Pharma: Q4 Earnings Insights
Earnings Preview: Lumos Pharma
Lumos Pharma FY 2023 Earnings Preview
See More Headlines
Receive LUMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/29/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LUMO
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$28.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+538.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-34,030,000.00
Net Margins
-1,659.39%
Pretax Margin
-1,660.80%

Debt

Sales & Book Value

Annual Sales
$2.05 million
Book Value
$3.45 per share

Miscellaneous

Free Float
6,186,000
Market Cap
$22.87 million
Optionable
Not Optionable
Beta
0.67
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Richard J. Hawkins (Age 75)
    Founder, CEO & Chairman
    Comp: $975.72k
  • Dr. John C. McKew Ph.D. (Age 60)
    Chief Scientific Officer & President
    Comp: $943.46k
  • Ms. Lori D. Lawley CPA (Age 40)
    CFO & Principal Accounting Officer
    Comp: $596.57k
  • Lisa Miller
    Senior Director of Investor Relations
  • Mr. Bradley J. Powers J.D. (Age 45)
    Chief Compliance Officer & General Counsel
    Comp: $677.08k
  • Mr. Aaron Schuchart B.B.A. (Age 58)
    CPA, M.B.A., Chief Business Officer
  • Dr. Pisit Pitukcheewanont FAAP
    M.D., Chief Medical Officer
  • Mr. Eddie L. Varnado M.B.A.
    Corporate Controller

LUMO Stock Analysis - Frequently Asked Questions

Should I buy or sell Lumos Pharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LUMO shares.
View LUMO analyst ratings
or view top-rated stocks.

What is Lumos Pharma's stock price target for 2024?

3 Wall Street analysts have issued 1 year price targets for Lumos Pharma's stock. Their LUMO share price targets range from $10.00 to $28.00. On average, they anticipate the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 538.3% from the stock's current price.
View analysts price targets for LUMO
or view top-rated stocks among Wall Street analysts.

How have LUMO shares performed in 2024?

Lumos Pharma's stock was trading at $3.18 at the start of the year. Since then, LUMO shares have decreased by 11.3% and is now trading at $2.82.
View the best growth stocks for 2024 here
.

When is Lumos Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our LUMO earnings forecast
.

How were Lumos Pharma's earnings last quarter?

Lumos Pharma, Inc. (NASDAQ:LUMO) announced its quarterly earnings results on Thursday, March, 7th. The company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.18) by $0.01. The business had revenue of $0.83 million for the quarter, compared to the consensus estimate of $0.01 million. Lumos Pharma had a negative trailing twelve-month return on equity of 85.63% and a negative net margin of 1,659.39%. During the same period last year, the business earned ($0.98) EPS.

What other stocks do shareholders of Lumos Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lumos Pharma investors own include Advanced Micro Devices (AMD), Agilent Technologies (A), Air Lease (AL), Bionano Genomics (BNGO), Chimerix (CMRX), Compagnie de Saint-Gobain (CODYY) and

Who are Lumos Pharma's major shareholders?

Lumos Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Blackstone Inc. (4.13%), Vanguard Group Inc. (3.01%), Vanguard Group Inc. (3.09%), Private Advisor Group LLC (0.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include John C Mckew, Kevin M Lalande, Kevin M Lalande, Richard J Hawkins and Thomas A Raffin.
View institutional ownership trends
.

How do I buy shares of Lumos Pharma?

Shares of LUMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LUMO) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners